However, when stratified by ZEB2 expression in the breast tumor, patients with high-ZEB2 levels demonstrated significantly lower survival probability than those with low-ZEB2 levels, with a median survival of 4267 days in low-ZEB2 expressors in contrast to 2965 days in high-ZEB2 patients (Fig. 5A). Here, ZEB2 is linked to breast neoplasm.